Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus (Nasdaq: BVS) has secured a new $400 million Senior Secured Credit Agreement, comprising a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement represents significant improvements over their 2019 Credit Agreement, featuring a 75 basis point reduction in interest margin, generating over $2 million in annual interest savings.
Key enhancements include an increase in revolving credit facility from $40 million to $100 million, and a reduction in annual term loan amortization from 10% to 5%. The company used the proceeds to repay its outstanding $333 million loan balance under the 2019 agreement, utilizing the new term loan, $30 million from the revolving facility, and $3 million cash on hand.
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new Peripheral Nerve Stimulation (PNS) products: TalisMann™ and StimTrial™. These innovative solutions target the rapidly growing PNS market, which is projected to exceed $500 million by 2029 with over 20% annual growth.
TalisMann™ combines electric field conduction technology with an integrated pulse generator for treating chronic nerve pain, while StimTrial™ enables physicians to evaluate patient response to PNS therapy. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026.
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its second quarter fiscal year 2025 earnings release and conference call. The company will announce its financial results before market open on Wednesday, August 6, 2025, followed by a management-hosted conference call at 8:30 a.m. Eastern Time.
Investors can participate by dialing 1-800-715-9871 (Conference ID: 1859022) or accessing the webcast through the company's investor relations website. The webcast recording will remain available for replay until August 5, 2026.
[]Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its first quarter fiscal year 2025 financial results announcement for May 6, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, where management will discuss the results and provide a business update.
Investors can participate by dialing 1-833-636-0497 and referencing the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until May 5, 2026.
Bioventus (BVS) reported strong Q4 2024 results with revenue reaching $153.6 million, up 13.5% year-over-year, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company reduced its net loss from continuing operations to $0.3 million, compared to $7.7 million in the prior year.
Full-year 2024 revenue totaled $573.3 million, representing an 11.9% increase, with organic growth of 14.4%. Adjusted EBITDA from continuing operations grew 22.5% to $108.9 million. The company successfully divested its Advanced Rehabilitation Business for $24.7 million and reduced long-term debt by $48.3 million in Q4.
Looking ahead, Bioventus projects 2025 revenue between $560-570 million, representing organic growth of 6.1-8.0%, and expects Adjusted EBITDA of $112-116 million with improved margins.
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its fourth quarter fiscal year 2024 financial results announcement for March 11, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring management discussion of results and business updates.
Investors can participate by dialing 1-833-636-0497 and referring to the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until March 10, 2026.
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, announced that its CEO, Rob Claypoole, will present at the 43rd Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A live webcast, including a Q&A session, will be accessible on the Investors section of the Bioventus website. This webcast will be available until February 15, 2025.
Bioventus (BVS) has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm specializing in HealthTech companies. The transaction, which was initially announced on October 1, 2024, has generated approximately $20 million in net closing proceeds for Bioventus, enhancing the company's liquidity position. This strategic move allows Bioventus to sharpen its focus and improve execution within its core business segments.
Bioventus (BVS) reported strong Q3 2024 financial results with revenue increasing 15.0% to $139.0 million. The company saw double-digit growth in Pain Treatments and Surgical Solutions. Net loss from continuing operations improved to $5.4 million compared to $8.8 million in the prior year. Adjusted EBITDA grew 8.4% to $23.6 million. The company raised its 2024 guidance, now expecting net sales of $562-567 million and reached an agreement to divest its Advanced Rehabilitation Business for up to $45.0 million.